Wednesday, April 22, 2026
33.4 C
Bengaluru

Opportunities for Indian Pharma

[wpfilebase tag=file id=75 tpl=download-button /]

Inside this Issue

1. Medical Rep to Country Head by Bhaskar Chakravorti
Bhaskar Chakravorti – Vice President, Micro Labs, talks about the growth of his career and his love for the country he presently calls ‘home’.

2. “Organizational Alignment Begins with a Common Vocabulary” by Hanno Wolfram
Our Editor Anup Soans sits down for a tête-à-tête with Hanno Wolfram – Owner, Innov8 and Member, MedicinMan Editorial Board.

3. Motivation: The No. 1 Challenge for Frontline Managers by K. Hariram
Motivation is created in teams only when ‘people’ and ‘purpose’ are prioritised.

4. A Pharma Technology Company Deeply Rooted in Experience by Krishna Singh
Krishna Singh spent 15 years in the Pharma Industry, beginning as a Medical Rep, before starting GlobalSpace technologies – a real Pharma field force multiplier.

5. Is Pharma Brand Management Promoting Mediocrity? by Shreenivas S
Simply hiring people because they have MBAs, without ascertaining their domain expertise or competency for the job, is a sure recipe for disaster. .

6. To Survive in the Jungle of Pharma Sales, Think like a Lion? by Chandan Kumar
Simple pointers to survive and thrive in the jungle of pharma sales.

7. Indian Pharma’s Many Challenges by Salil Kallianpur
The Indian Pharma Industry faces a multitude of challenges (and opportunities), some of which are unique to different sets of players, such as domestic Co’s and MNCs.

Hot this week

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Topics

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img